Journal article · 2025 · Open access
NEW PATIENT-REPORTED OUTCOME MEASURES FOR EARLY SYSTEMIC SCLEROSIS USING THE FDA GUIDANCE ON PATIENT REPORTED OUTCOME MEASURES
Annals of the Rheumatic Diseases, 84, 1064 · Published 1 June 2025 · DOI 10.1016/j.ard.2025.06.296
In brief
“NEW PATIENT-REPORTED OUTCOME MEASURES FOR EARLY SYSTEMIC SCLEROSIS USING THE FDA GUIDANCE ON PATIENT REPORTED OUTCOME MEASURES” is a 2025 journal article by D. Khanna and 5 co-authors, published in Annals of the Rheumatic Diseases. OpenAlex counts 1 citations as of 22 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Annals of the Rheumatic Diseases.
- Citations
- 1
- Most cited in
- 2026 (1)
- Authors
- 6
Abstract
Background: Systemic sclerosis (SSc) is associated with a wide range of symptoms and significant impairments in function and quality of life. Objectives: The goal of the Clinical Outcome Assessments for Systemic Sclerosis Clinical Trials (COAST) Project was to construct robust SSc-specific, patient-reported outcome (PRO) measures for early SSc clinical trials. Methods: We constructed the COAST Candidate Measures in a 6-step process: 1) Conducted qualitative concept elicitation interviews (CEIs) in patients with SSc, 2) Conducted concept mapping analysis to identify conceptual domains that emerged from the CEI data, 3) Prioritized concepts and identified conceptual gaps by conducting mixed methods analysis and leveraging SSc disease expert input, 4) Developed the item pool by utilizing existing resources (HealthMeasures Ⓡ , FDA Voice of the Patient Report, available SSc-specific measures), 5) Reduced the item pool through clinical and research expert review, and 6) Constructed the candidate SSc PRO measures. Results: 42 participants (21 each with limited cutaneous SSc (lcSSc) and diffuse cutaneous (dcSSc)) with disease duration of <7 years (from first non-Raynaud's phenomenon sign or symptom) were recruited at a scleroderma clinic. This sample size was sufficient to elicit a comprehensive list of symptoms, treatment side effects (TSEs), and impacts for each patient group and achieve thematic saturation. Participants reported 76 symptoms/TSEs (or concepts). Concepts identified as not a SSc symptom or TSEs by expert review were dropped and a total of 52 unique symptoms/TSEs were mapped into 16 domains. Of these 52 concepts, 34 (65.4%) were reported by participants representing both subtypes of SSc; 13 (25.0%) and 5 (9.6%) were reported only by participants with dcSSc and lcSSc, respectively. We mapped these concepts to existing items from PROMIS item banks, FACIT item banks, the draft CRISTAL measure (in development), and the SSPRO measure. We selected the items that would be considered most proximal to a PRO endpoint model as comprising the primary clinical trial instrument. This instrument is considered as a measure of the most likely direct effects of treatment, with its focus on SSc symptoms and TSEs. The items set aside earlier were found to focus on symptom impacts, physical function, and general quality of life concerns. Two candidate measures were therefore produced: COAST Symptoms and Side Effects Questionnaire (v1.0 ) is a 33-item candidate measure covering 11 domains and 27 concepts for clinical trials (Figure 1); COAST Function and Life Quality Questionnaire (v1.0 ) is a 20-item candidate measure covering 8 domains and 17 concepts as a complementary measure. Conclusion: We developed preliminary COAST questionnaires for use as outcome measures in…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Khanna, D., Greene, G., Perschon, C. R., Lescoat, A., Murphy, S. L., & Cella, D. F. (2025). NEW PATIENT-REPORTED OUTCOME MEASURES FOR EARLY SYSTEMIC SCLEROSIS USING THE FDA GUIDANCE ON PATIENT REPORTED OUTCOME MEASURES. Annals of the Rheumatic Diseases, 84, 1064. https://doi.org/10.1016/j.ard.2025.06.296
MLA 9
Khanna, D., et al. “NEW PATIENT-REPORTED OUTCOME MEASURES FOR EARLY SYSTEMIC SCLEROSIS USING THE FDA GUIDANCE ON PATIENT REPORTED OUTCOME MEASURES.” Annals of the Rheumatic Diseases, vol. 84, 2025, p. 1064. https://doi.org/10.1016/j.ard.2025.06.296.
Chicago
Khanna, D., G. Greene, Chelsea Rose Perschon, Alain Lescoat, Susan Lynn Murphy, and David F Cella. 2025. “NEW PATIENT-REPORTED OUTCOME MEASURES FOR EARLY SYSTEMIC SCLEROSIS USING THE FDA GUIDANCE ON PATIENT REPORTED OUTCOME MEASURES.” Annals of the Rheumatic Diseases 84: 1064. https://doi.org/10.1016/j.ard.2025.06.296.
Harvard
Khanna, D. et al. (2025) ‘NEW PATIENT-REPORTED OUTCOME MEASURES FOR EARLY SYSTEMIC SCLEROSIS USING THE FDA GUIDANCE ON PATIENT REPORTED OUTCOME MEASURES’, Annals of the Rheumatic Diseases, 84, p. 1064. doi:10.1016/j.ard.2025.06.296.
IEEE
D. Khanna, G. Greene, C. R. Perschon, A. Lescoat, S. L. Murphy, and D. F. Cella, “NEW PATIENT-REPORTED OUTCOME MEASURES FOR EARLY SYSTEMIC SCLEROSIS USING THE FDA GUIDANCE ON PATIENT REPORTED OUTCOME MEASURES,” Annals of the Rheumatic Diseases, vol. 84, p. 1064, 2025, doi: 10.1016/j.ard.2025.06.296.
BibTeX
@article{khanna2025patient,
title = {{NEW PATIENT-REPORTED OUTCOME MEASURES FOR EARLY SYSTEMIC SCLEROSIS USING THE FDA GUIDANCE ON PATIENT REPORTED OUTCOME MEASURES}},
author = {Khanna, D. and Greene, G. and Perschon, Chelsea Rose and Lescoat, Alain and Murphy, Susan Lynn and Cella, David F},
journal = {Annals of the Rheumatic Diseases},
year = {2025},
volume = {84},
pages = {1064},
doi = {10.1016/j.ard.2025.06.296},
url = {https://doi.org/10.1016/j.ard.2025.06.296}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- systemic sclerosis
- patient-reported outcome measures
- limited cutaneous systemic sclerosis
- diffuse cutaneous systemic sclerosis
- concept mapping
- concept elicitation interviews
- treatment side effects
- symptom domains
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Khanna, D., Greene, G., Perschon, C. R., Lescoat, A., Murphy, S. L., & Cella, D. F. (2025). NEW PATIENT-REPORTED OUTCOME MEASURES FOR EARLY SYSTEMIC SCLEROSIS USING THE FDA GUIDANCE ON PATIENT REPORTED OUTCOME MEASURES. Annals of the Rheumatic Diseases, 84, 1064. https://doi.org/10.1016/j.ard.2025.06.296
How many times has this paper been cited?
1 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Annals of the Rheumatic Diseases: sign in and open the full text from this page.
Who wrote this paper?
D. Khanna, G. Greene, Chelsea Rose Perschon, Alain Lescoat, Susan Lynn Murphy, David F Cella.
What is the DOI of this paper?
10.1016/j.ard.2025.06.296, permanently at https://doi.org/10.1016/j.ard.2025.06.296. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.